Literature DB >> 34939675

Neutrophil extracellular traps drive epithelial-mesenchymal transition of human colon cancer.

Antonia M Stehr1, Guangxia Wang1, Richard Demmler1, Marc P Stemmler2, Julia Krug1, Philipp Tripal3, Benjamin Schmid3, Carol I Geppert4, Arndt Hartmann4, Luis E Muñoz5,6, Janina Schoen5,6, Simon Völkl7, Susanne Merkel8, Christoph Becker9, Georg Schett5,6, Robert Grützmann8, Elisabeth Naschberger1, Martin Herrmann5,6, Michael Stürzl1,10.   

Abstract

Neutrophil extracellular traps (NETs) are extracellular structures, composed of nuclear DNA and various proteins released from neutrophils. Evidence is growing that NETs exert manifold functions in infection, immunity and cancer. Recently, NETs have been detected in colorectal cancer (CRC) tissues, but their association with disease progression and putative functional impact on tumourigenesis remained elusive. Using high-resolution stimulated emission depletion (STED) microscopy, we showed that citrullinated histone H3 (H3cit) is sufficient to specifically detect citrullinated NETs in colon cancer tissues. Among other evidence, this was supported by the close association of H3cit with de-condensed extracellular DNA, the hallmark of NETs. Extracellular DNA was reliably differentiated from nuclear condensed DNA by staining with an anti-DNA antibody, providing a novel and valuable tool to detect NETs in formalin-fixed paraffin-embedded tissues. Using these markers, the clinical association of NETs was investigated in a cohort of 85 patients with colon cancer. NETs were frequently detected (37/85, 44%) in colon cancer tissue sections and preferentially localised either only in the tumour centre or both in the tumour centre and the invasive front. Of note, citrullinated NETs were significantly associated with high histopathological tumour grades and lymph node metastasis. In vitro, purified NETs induced filopodia formation and cell motility in CRC cell lines. This was associated with increased expression of mesenchymal marker mRNAs (vimentin [VIM], fibronectin [FN1]) and epithelial-mesenchymal transition promoting transcription factors (ZEB1, Slug [SNAI2]), as well as decreased expression of the epithelial markers E-cadherin (CDH1) and epithelial cell adhesion molecule (EPCAM). These findings indicated that NETs activate an epithelial-mesenchymal transition-like process in CRC cells and may contribute to the metastatic progression of CRC.
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Entities:  

Keywords:  colorectal neoplasms; epithelial-mesenchymal transition (EMT); extracellular traps; migration; neutrophils; stimulated emission depletion (STED) microscopy

Mesh:

Substances:

Year:  2022        PMID: 34939675     DOI: 10.1002/path.5860

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  4 in total

Review 1.  Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated.

Authors:  Keywan Mortezaee; Jamal Majidpoor; Ebrahim Kharazinejad
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

Review 2.  Tumor regionalization after surgery: Roles of the tumor microenvironment and neutrophil extracellular traps.

Authors:  Su-Bin Kwak; Sang Jin Kim; Jiyoung Kim; Ye-Lim Kang; Chang Woo Ko; Iljin Kim; Jong-Wan Park
Journal:  Exp Mol Med       Date:  2022-06-28       Impact factor: 12.153

3.  RNA Binding Motif Protein 3 Promotes Cell Metastasis and Epithelial-Mesenchymal Transition Through STAT3 Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Lu Zhang; Yi Zhang; Dongliang Shen; Ying Chen; Jianguo Feng; Xing Wang; Lunkun Ma; Yi Liao; Liling Tang
Journal:  J Hepatocell Carcinoma       Date:  2022-05-09

Review 4.  Neutrophil extracellular traps: New players in cancer research.

Authors:  Junjie Zhao; Jiaqi Jin
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.